Condition: Biliary Tract Cancer · Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
This description comes directly from the study's public registry record.
Feng Shen, Doctor · 13901651428 · shenfengehbh@sina.com
Jun Zhou, Doctor · 13366152815 · 13366152815@126.com
Always discuss trial participation with your own doctor first.
| Fuyang Cancer Hospital | Fuyang, Anhui, China | Not Yet Recruiting |
| Anhui Second People's Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Cancer Hospital Chinese Academy of Medical Science | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Tsinghua Changgeng Hospital, Beijing | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Fujian Provincial Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Gansu Provincial Tumor Hospital | Lanzhou, Gansu, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | Not Yet Recruiting |
+ 31 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06431490